The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2025 | Practical advice for physicians treating patients with myeloma using belantamab mafodotin
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, offers practical guidance for physicians treating patients with multiple myeloma (MM) using belantamab mafodotin. Prof. Lonial emphasizes the importance of collaborating with an eye care provider to monitor ocular side effects. He also advises adopting longer dosing intervals, highlighting his center’s approach of starting with eight-week dosing followed by 12-week dosing. This interview took place at the 11th World Congress on Controversies in Multiple Myeloma (COMy) congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, I think the key again is to find an eye care partner that you can work with. It doesn’t have to be an ophthalmologist, it can be an optometrist. Make sure that you do give that first dose, but then consider spreading the dose beyond that. At our center, we have a trial of maintenance bela, where we start with every eight week dosing and then we go to every 12 week dosing after that...
Well, I think the key again is to find an eye care partner that you can work with. It doesn’t have to be an ophthalmologist, it can be an optometrist. Make sure that you do give that first dose, but then consider spreading the dose beyond that. At our center, we have a trial of maintenance bela, where we start with every eight week dosing and then we go to every 12 week dosing after that. You don’t have to hammer on with the every three week dosing or even every four week dosing. It’s just not necessary in almost all patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
